In a Lexpert article exploring how advance knowledge of the U.S. Treasury Department’s anti-inversion regulations has lessened their impact, Davies partner Hillel Rosen discusses the M&A boom in life sciences. “We’re reading about inversion, but the real story is that M&A is the new R&D,” says Hillel. “It incorporates the notion that you can be a pharma company without spending a dollar in research.”
Federal Budget 2024: How It Impacts You and Your Business
Apr. 16, 2024 - On April 16, 2024 (Budget Day) the Honourable Chrystia Freeland, Deputy Prime Minister of Canada and Minister of Finance, delivered the Liberal Party’s federal budget (Budget 2024). Budget 2024 included a number of proposed changes to the Income Tax Act (ITA) and other tax legislation. ...
Governance Insights: 10 Trends that GCs and Boards Need to Know
Jan. 24, 2024 - The latest edition of Davies’ Governance Insights is now available. In this issue, we explore 10 important trends that will help general counsel and boards navigate the year ahead. In order to help you with your strategic and compliance planning, we discuss issues including the...
